#Denmark #Copenhagen #Biocodex #PrecisionBiotics #Alflorex

Strengthening Microbiome Solutions: The New Phase of Partnership Between PrecisionBiotics and Biocodex

On April 23, 2026, in Copenhagen, Denmark, PrecisionBiotics®, a subsidiary of Novonesis, and the French pharmaceutical firm Biocodex formalized the next step in their collaborative journey. At a strategic leadership meeting, the two companies signed a new agreement aimed at enhancing their partnership and reinforcing their joint commitment to advancing microbiome science, ultimately benefiting consumers and patients worldwide.

A Proven Partnership

The collaboration between PrecisionBiotics and Biocodex spans an impressive nine years. Over this period, both organizations have invested in developing and promoting clinically proven solutions based on microbiome science. This new agreement symbolizes not only a renewal of their commitment but also a celebration of their past successes.

Biocodex has been instrumental in facilitating the international growth of PrecisionBiotics’ Consumer Health brands, wisely expanding their reach across multiple markets. With a focus on microbiota, this partnership thrives on shared ambition and consistent performance, creating a solid foundation for future initiatives.

Goals for the New Partnership Phase

The new agreement is designed to accelerate growth further by extending the reach of key products while enhancing scientific collaboration. This means unlocking new opportunities that span both the current markets and those that are yet to be explored. Regional Director of Consumer Health at Novonesis, Cris Burson-Thomas, highlighted the effectiveness of their partnership, stating, “Our partnership has demonstrated what can be achieved when strong science is combined with deep market expertise.”

As they embark on this next chapter, both companies are enthusiastic about broadening access to clinically verified microbiome solutions while setting a new standard for innovation in the field.

The Role of Alflorex®

One of the standout products from PrecisionBiotics is their flagship probiotic, Alflorex®, which contains the clinically researched strain Bifidobacterium longum 35624™. Launched in 2014, Alflorex® has become a leading solution in digestive health and has successfully entered more than 15 countries through Biocodex's extensive portfolio, achieving significant market positions in various key European regions.

PrecisionBiotics, established over two decades ago as a science-led microbiome company, is known for developing clinically researched probiotic strains tailored to specific health requirements. Now part of Novonesis—a global leader in biosolutions formed from the merger of Novozymes and Chr. Hansen—PrecisionBiotics boasts one of the world’s largest collections of bacterial strains and enzymes, enabling them to deliver innovative and sustainable health solutions.

Looking Ahead: Biocodex's Perspective

From Biocodex's viewpoint, this renewed partnership is pivotal for their strategic focus on microbiota innovation. CEO Nicolas Coudurier emphasized that strengthening ties with Novonesis reinforces their ambitions to push for innovation and growth in microbiome science, thereby providing high-quality, evidence-based solutions to an expanding patient base globally.

In conclusion, the partnership between PrecisionBiotics and Biocodex marks a promising opportunity in microbiome science. As they advance this collaboration, both organizations remain committed to transforming available solutions into accessible, science-backed health products. With new goals firmly in place, stakeholders can look forward to exciting developments in health solutions that are informed by rigorous research and innovative practices.